Literature DB >> 21525158

Triglyceride response to an intensive lifestyle intervention is enhanced in carriers of the GCKR Pro446Leu polymorphism.

Toni I Pollin1, Kathleen A Jablonski, Jarred B McAteer, Richa Saxena, Sekar Kathiresan, Steven E Kahn, Ronald B Goldberg, David Altshuler, Jose C Florez.   

Abstract

CONTEXT: Glucokinase regulatory protein (GCKR) regulates the trafficking and enzymatic activity of hepatic glucokinase, the rate-limiting enzyme in glycogen synthesis and glycolysis. The intronic single-nucleotide polymorphism (SNP) rs780094 (intron 16) and the missense SNP rs1260326 (P446L) in the GCKR gene are strongly associated with increased circulating triglyceride and C-reactive protein levels and, paradoxically, reductions in diabetes incidence, fasting glucose levels, and insulin resistance. OBJECTIVE, SETTING, AND PATIENTS: We sought to replicate these associations and evaluate interactions with lifestyle and metformin interventions in the multiethnic Diabetes Prevention Program (DPP). INTERVENTIONS AND MAIN OUTCOME MEASURES: We genotyped the two GCKR SNP in 3346 DPP participants and evaluated association with progression to diabetes and both baseline levels and changes in triglycerides, homeostasis model assessment of insulin resistance (HOMA-IR), oral disposition index, and inflammatory markers along with their interactions with DPP interventions.
RESULTS: GCKR variation did not predict development of type 2 diabetes. At baseline, the 446L allele was associated with higher triglyceride and C-reactive protein levels (both P < 0.0001) and lower fasting glucose (P = 0.001) and HOMA-IR (P = 0.06). The lifestyle intervention was associated with a decrease in magnitude of the effect of the 446L allele on triglyceride levels (interaction P = 0.04). Metformin was more effective in reducing HOMA-IR in carriers of the P446 allele (interaction P = 0.05).
CONCLUSIONS: Intensive lifestyle intervention appears to partially mitigate the effect of the 446L allele on higher triglycerides, whereas the P446 allele appears to enhance responsiveness to the HOMA-IR-lowering effect of metformin.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21525158      PMCID: PMC3205512          DOI: 10.1210/jc.2010-2324

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  25 in total

1.  Inference of population structure using multilocus genotype data.

Authors:  J K Pritchard; M Stephens; P Donnelly
Journal:  Genetics       Date:  2000-06       Impact factor: 4.562

2.  Effect of metformin on fatty acid and glucose metabolism in freshly isolated hepatocytes and on specific gene expression in cultured hepatocytes.

Authors:  J P Fulgencio; C Kohl; J Girard; J P Pégorier
Journal:  Biochem Pharmacol       Date:  2001-08-15       Impact factor: 5.858

3.  The GCKR rs780094 polymorphism is associated with elevated fasting serum triacylglycerol, reduced fasting and OGTT-related insulinaemia, and reduced risk of type 2 diabetes.

Authors:  T Sparsø; G Andersen; T Nielsen; K S Burgdorf; A P Gjesing; A L Nielsen; A Albrechtsen; S S Rasmussen; T Jørgensen; K Borch-Johnsen; A Sandbaek; T Lauritzen; S Madsbad; T Hansen; O Pedersen
Journal:  Diabetologia       Date:  2007-11-16       Impact factor: 10.122

4.  Enzymatic methods for quantification of lipoprotein lipids.

Authors:  G R Warnick
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

5.  Trends in serum lipids and lipoproteins of adults, 1960-2002.

Authors:  Margaret D Carroll; David A Lacher; Paul D Sorlie; James I Cleeman; David J Gordon; Michael Wolz; Scott M Grundy; Clifford L Johnson
Journal:  JAMA       Date:  2005-10-12       Impact factor: 56.272

6.  The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes.

Authors: 
Journal:  Diabetes Care       Date:  1999-04       Impact factor: 19.112

7.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

Authors:  William C Knowler; Elizabeth Barrett-Connor; Sarah E Fowler; Richard F Hamman; John M Lachin; Elizabeth A Walker; David M Nathan
Journal:  N Engl J Med       Date:  2002-02-07       Impact factor: 91.245

8.  Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.

Authors:  D R Matthews; J P Hosker; A S Rudenski; B A Naylor; D F Treacher; R C Turner
Journal:  Diabetologia       Date:  1985-07       Impact factor: 10.122

9.  Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels.

Authors:  Richa Saxena; Benjamin F Voight; Valeriya Lyssenko; Noël P Burtt; Paul I W de Bakker; Hong Chen; Jeffrey J Roix; Sekar Kathiresan; Joel N Hirschhorn; Mark J Daly; Thomas E Hughes; Leif Groop; David Altshuler; Peter Almgren; Jose C Florez; Joanne Meyer; Kristin Ardlie; Kristina Bengtsson Boström; Bo Isomaa; Guillaume Lettre; Ulf Lindblad; Helen N Lyon; Olle Melander; Christopher Newton-Cheh; Peter Nilsson; Marju Orho-Melander; Lennart Råstam; Elizabeth K Speliotes; Marja-Riitta Taskinen; Tiinamaija Tuomi; Candace Guiducci; Anna Berglund; Joyce Carlson; Lauren Gianniny; Rachel Hackett; Liselotte Hall; Johan Holmkvist; Esa Laurila; Marketa Sjögren; Maria Sterner; Aarti Surti; Margareta Svensson; Malin Svensson; Ryan Tewhey; Brendan Blumenstiel; Melissa Parkin; Matthew Defelice; Rachel Barry; Wendy Brodeur; Jody Camarata; Nancy Chia; Mary Fava; John Gibbons; Bob Handsaker; Claire Healy; Kieu Nguyen; Casey Gates; Carrie Sougnez; Diane Gage; Marcia Nizzari; Stacey B Gabriel; Gung-Wei Chirn; Qicheng Ma; Hemang Parikh; Delwood Richardson; Darrell Ricke; Shaun Purcell
Journal:  Science       Date:  2007-04-26       Impact factor: 47.728

10.  Mlx is the functional heteromeric partner of the carbohydrate response element-binding protein in glucose regulation of lipogenic enzyme genes.

Authors:  Angela K Stoeckman; Lin Ma; Howard C Towle
Journal:  J Biol Chem       Date:  2004-01-23       Impact factor: 5.157

View more
  18 in total

Review 1.  The Continuing Evolution of Precision Health in Type 2 Diabetes: Achievements and Challenges.

Authors:  Yuan Lin; Jennifer Wessel
Journal:  Curr Diab Rep       Date:  2019-02-26       Impact factor: 4.810

2.  Effects of a glucokinase activator on hepatic intermediary metabolism: study with 13C-isotopomer-based metabolomics.

Authors:  Itzhak Nissim; Oksana Horyn; Ilana Nissim; Yevgeny Daikhin; Suzanne L Wehrli; Marc Yudkoff; Franz M Matschinsky
Journal:  Biochem J       Date:  2012-06-15       Impact factor: 3.857

3.  Polymorphisms in the GCKR are associated with serum lipid traits, the risk of coronary artery disease and ischemic stroke.

Authors:  Yi-Jiang Zhou; Shao-Cai Hong; Rui-Xing Yin; Qian Yang; Xiao-Li Cao; Wu-Xian Chen
Journal:  Int J Clin Exp Med       Date:  2015-07-15

Review 4.  Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program.

Authors:  Ronald B Goldberg; Kieren Mather
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-09       Impact factor: 8.311

5.  The GCKR Gene Polymorphism rs780094 is a Risk Factor for Gestational Diabetes in a Brazilian Population.

Authors:  Mauren Isfer Anghebem-Oliveira; Susan Webber; Dayane Alberton; Emanuel Maltempi de Souza; Giseli Klassen; Geraldo Picheth; Fabiane Gomes de Moraes Rego
Journal:  J Clin Lab Anal       Date:  2016-08-24       Impact factor: 2.352

Review 6.  Advances in exercise, fitness, and performance genomics in 2011.

Authors:  Stephen M Roth; Tuomo Rankinen; James M Hagberg; Ruth J F Loos; Louis Pérusse; Mark A Sarzynski; Bernd Wolfarth; Claude Bouchard
Journal:  Med Sci Sports Exerc       Date:  2012-05       Impact factor: 5.411

7.  Maternal genotype and gestational diabetes.

Authors:  Alison M Stuebe; Alison Wise; Thutrang Nguyen; Amy Herring; Kari E North; Anna Maria Siega-Riz
Journal:  Am J Perinatol       Date:  2013-03-01       Impact factor: 1.862

8.  Lifestyle Intervention for Weight Loss and Cardiometabolic Changes in the Setting of Glucokinase Regulatory Protein Inhibition: Glucokinase Regulatory Protein-Leu446Pro Variant in Look AHEAD.

Authors:  L Maria Belalcazar; George D Papandonatos; Bahar Erar; Inga Peter; Hadeel Alkofide; Ashok Balasubramanyam; Ariel Brautbar; Steven E Kahn; William C Knowler; Christie M Ballantyne; Jeanne M McCaffery; Gordon S Huggins
Journal:  Circ Cardiovasc Genet       Date:  2015-11-17

9.  Genetic variation at NCAN locus is associated with inflammation and fibrosis in non-alcoholic fatty liver disease in morbid obesity.

Authors:  Alexis Gorden; Rongze Yang; Laura M Yerges-Armstrong; Kathleen A Ryan; Elizabeth Speliotes; Ingrid B Borecki; Tamara B Harris; Xin Chu; G Craig Wood; Christopher D Still; Alan R Shuldiner; Glenn S Gerhard
Journal:  Hum Hered       Date:  2013-04-10       Impact factor: 0.444

10.  Do genetic modifiers of high-density lipoprotein cholesterol and triglyceride levels also modify their response to a lifestyle intervention in the setting of obesity and type-2 diabetes mellitus?: The Action for Health in Diabetes (Look AHEAD) study.

Authors:  Gordon S Huggins; George D Papandonatos; Bahar Erar; L Maria Belalcazar; Ariel Brautbar; Christie Ballantyne; Abbas E Kitabchi; Lynne E Wagenknecht; William C Knowler; Henry J Pownall; Rena R Wing; Inga Peter; Jeanne M McCaffery
Journal:  Circ Cardiovasc Genet       Date:  2013-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.